Author

admin

Browsing

We’ve seen this before: fear, overregulation, and political hubris at the dawn of an economic breakthrough. Will we learn from history — or repeat its mistakes?

In every era of transformation, one thing never changes: politicians panic.

When the agricultural revolution spread through Europe and into the early American colonies, it upended social orders. Elites feared farmers with new tools would abandon the land. During the Industrial Revolution, steam power and factory machines were labeled threats to jobs and morality. And in the digital age, the rise of the internet was met with a flurry of federal blue-ribbon panels warning about everything from pornography to “cyberspace addiction.”

Now comes artificial intelligence — the next great leap in human productivity — and the cycle is repeating itself. Only this time, the stakes are global, and the timeline is faster.

Last week, the Trump administration released its AI Action Plan — a significant course correction from the Biden years that scraps top-down federal control and embraces innovation through deregulation, investment, and infrastructure. It’s one of the most pro-market approaches to AI policy we’ve seen from any Western government.

However, while the plan’s vision is mostly correct, it lacks a crucial protection: a federal moratorium on state-level AI regulation. That omission leaves the door wide open for 50 different states to suffocate innovation under 50 different bureaucratic regimes.

This Moment Is America’s to Lose

Artificial intelligence isn’t a robot uprising — it’s advanced computing, a continuation of decades of machine learning, data science, and automation. Like past revolutions, it is a general-purpose technology with a massive upside: from medical diagnostics to precision agriculture, logistics, and personalized education.

This is the beginning of a transformation on par with the printing press, the steam engine, and the internet. Yet like every leap forward, it’s greeted with a mix of excitement and fear. And fear tends to invite government overreach.

Entrepreneurs don’t know exactly what AI will look like ten years from now — but they have vastly more insight than politicians ever will, because they live in the feedback loops of real-time trial and error. Markets discover. Governments delay.

Just look at where capital is going: AI startups raised $104 billion in the first half of 2025 alone — more than in any full year prior. Guggenheim analysts expect even larger gains ahead as enterprise adoption continues to soar.

This may not be a bubble but a boom. And America is positioned to lead — if we don’t regulate ourselves into stagnation.

Can Washington Rein in the States?

Some may question whether the federal government has the constitutional authority to stop states from regulating AI. The answer is yes — when interstate commerce is clearly involved, as it is with nearly every AI tool, system, and application. From cloud infrastructure to multi-state model deployment to international data flows, AI is not a local matter. It’s a global one.

The US Constitution empowers Congress to “regulate Commerce… among the several States,” and the courts have long upheld federal preemption in nationally integrated markets. In Gibbons v. Ogden (1824), the Supreme Court made it clear: when a state law interferes with the free flow of interstate commerce, the federal government has both the right and duty to act.

As James Madison wrote in Federalist No. 42, the Commerce Clause was essential to “guard against the many practices… which have hitherto embarrassed the intercourse of the States.” That applies perfectly to today’s AI patchwork.

While states have roles to play, they should not be left to erect legal walls around innovation or preempt national policy through fear and overreach. A temporary moratorium, while aggressive, would be both constitutional and necessary to ensure America doesn’t fumble the biggest economic opportunity in a generation.

The Trump Plan Is Pro-Growth, but the States Are a Risk

Fortunately, Trump’s new Executive Order 14179 repealed Biden’s restrictive EO 14110, which had empowered bureaucrats to embed fairness checks and ideological audits in AI tools. That approach mirrored the EU’s bloated AI Act — and would have ensured US developers got bogged down in red tape while China continued to advance.

The new federal plan rejects that path. It commits to:

  • Cutting permitting delays for AI infrastructure and semiconductor fabs
  • Encouraging open-weight AI models to foster competition
  • Expanding workforce education and employer training with fewer tax penalties
  • Prioritizing innovation over precaution

This is the right vision. But without a preemptive strike against state overreach, it may be impossible to implement in practice.

The House-passed version of Trump’s One Big Beautiful Bill (OBBB) included a federal moratorium on new state AI regulations. That language was dropped by the Senate before final passage. The expected result is chaos.

State Capitols Are Legislating Blind

In 2025 alone, more than 1,000 AI-related bills were introduced across all 50 states — up from nearly 700 in 2024, according to the James Madison Institute. The National Conference of State Legislatures confirms that dozens of those have already become law.

Here’s the problem: these aren’t coherent guardrails — they’re preemptive policy panic.

  • California wants every AI output evaluated for “equity harms,” whatever that means.
  • New York is pushing for AI licensing boards and pre-release approvals.
  • Even Texas, which often leads in free-market policy, passed HB 149 (TRAIGA), creating a new bureaucracy to oversee so-called “high-risk” AI applications. It’s better than where it started, but still opens the door to creeping state control.

This is not just regulatory noise — it’s a threat to the scalability of American innovation. It fragments compliance and deters investment, particularly in open-source or startup environments.

Don’t Let History Repeat

Every time a new tool comes along that threatens old structures, lawmakers feel the need to “do something.” But as Milton Friedman taught us, the government solution to a problem is usually worse than the problem.

In truth, the best response to AI fear may be no response at all — at least not yet. We already have laws on the books to address fraud, discrimination, theft, and safety. We don’t need to build new bureaucracies to police speculative harms that may never materialize.

The biggest risk is not that AI goes rogue. It’s that our political class chokes off its development with regulatory hubris.

The EU is already moving in that direction. And while China may look fast on the surface, it’s doing so through central planning and repression, which ultimately stifles the kind of open innovation that gave the world the microchip and the internet.

America can still lead. But it must do so by trusting markets, not mandates.

Let Parents and Entrepreneurs Lead

Rather than preemptively outlawing AI tools in classrooms or forcing private businesses to submit models for approval, we should let parents, workers, students, and entrepreneurs decide what works best for them.

We don’t need governors and attorneys general positioning themselves as AI overlords to score political points. We need an environment where knowledge creation is decentralized, experimentation is encouraged, and failure is an integral part of the process.

Just as in the past, those who fear the new are demanding power over it. But history tells us: the real danger is not the technology — it’s the legislation that follows fear.

Give Innovation a Fighting Chance

The Trump administration’s AI Action Plan is a welcome course correction. It prioritizes innovation over regulation, removes ideological roadblocks, and trusts the market to do what it does best — discover, adapt, and grow.

But unless Congress follows through with a moratorium on new state AI laws, this moment of opportunity will collapse under a pile of conflicting mandates and political micromanagement. We can’t lead the world while tripping over our own red tape.

We’ve seen this before. Every great economic revolution — agriculture, industry, technology — was nearly smothered by fear and top-down control. We can’t afford to make the same mistake with artificial intelligence.

Let’s stop pretending politicians know what’s coming next. They don’t. Entrepreneurs have a better shot — not because they’re perfect, but because they’re accountable to reality, not to reelection.

Congress should act now. Delay the deluge of state AI regulation. Let existing laws do their job. And give this generation’s innovators the space to build the future. That’s how America wins the AI race — not with more government, but with more freedom.

When Canadian-Russian programmer Vitalik Buterin penned a white paper in 2013 outlining a new kind of blockchain platform, few could have predicted the seismic impact it would have on the world of finance, technology, and beyond.

Today (July 30), Ethereum turns 10 years old, marking a milestone that represents a decade of one of the most influential blockchain platforms and a testament to the growing pains, triumphs, and resilience of the decentralized movement.

How did Ethereum go from a white paper drafted by a 19-year-old to a billion-dollar ecosystem that reshaped global finance?

Read on to find out more.

What is Ethereum and who invented it?

Co-founder Buterin said in a 2016 interview that Ethereum was born out of admiration for Bitcoin’s decentralized structure and frustration at its limited capabilities.

“I thought [those in the Bitcoin community] weren’t approaching the problem in the right way. I thought they were going after individual applications; they were trying to kind of explicitly support each [use case] in a sort of Swiss Army knife protocol,” Buterin said, summarizing his motivation to build something more adaptable.

From this foundational idea, Ethereum emerged as a decentralized, programmable blockchain — a “world computer” that would host smart contracts and decentralized applications (dApps), cutting out middlemen and enabling new forms of coordination.

The foundation of the fledgling project was laid between 2013 and 2014. After releasing his white paper in late 2013, Buterin attracted a handful of co-founders, including Gavin Wood, Charles Hoskinson, Joseph Lubin, Anthony Di Iorio, Jeffrey Wilcke, Mihai Alisie, and Amir Chetrit. Together, they spearheaded a crowdfunding campaign in mid-2014 that raised over US$18 million, one of the earliest and most successful Initial Coin Offerings (ICOs) in crypto history.

Despite this momentum, the Ethereum blockchain didn’t launch until July 30, 2015. That release, dubbed “Frontier,” was a basic, raw, and developer-focused version of Ethereum designed for building the infrastructure that would follow.

ETH, Ethereum’s native coin, initially traded for under a dollar. The early months saw little market movement as ETH hovered between US$0.70 and US$2.00, supported mainly by enthusiasts and developers interested in dApp potential.

When was Ethereum’s first major peak?

Ethereum’s first major price rally came during the 2017 crypto bull run, when rising global interest in blockchain technology and the initial coin offering (ICO) boom brought ETH into the mainstream.

After beginning the year at just barely US$8, Ethereum surged to a then-record high of around US$1,400 by January 2018, capping off one of the most explosive price increases in the history of digital assets. This more than 17,000 percent rise was driven by a combination of speculative demand and the emergence of Ethereum as the preferred platform for launching new tokens via ICOs.

By early 2018, however, the market began to reverse. A sweeping crypto correction saw Ethereum’s price fall back below US$100 by the end of that year. The drawdown exposed Ethereum’s technical bottlenecks, such as high gas fees and slow confirmation times during network congestion.

What was the DAO Hack, and how did it influence Ethereum’s trajectory?

Ethereum’s ethos of decentralization was also tested early on. In 2016, an experiment in decentralized governance — the Decentralized Autonomous Organization or DAO — raised about US$150 million in ETH from the community. The idea was to create a venture capital fund governed entirely by smart contracts and token-holder votes.

But just weeks after launch, a vulnerability in the DAO’s code that allowed for recursive call exploit was discovered, draining 3.6 million ETH or about a third of the fund.

At just ten months old, Ethereum was now facing a crisis that tested its fundamental principles, chief among them the immutability of the blockchain and the inviolability of smart contracts.

Three primary responses were debated. One option was to do nothing, honoring the hacker’s actions as legitimate under the rules of the code and accepting the theft. Another was to implement a “soft fork” that would blacklist the child DAO’s address, effectively freezing the stolen funds.

The most radical option was a “hard fork” that would roll back the ledger and return all stolen Ether to the original investors, which would undo the hack entirely.

Ultimately, the hard fork went ahead, and Ethereum split into two chains: the main Ethereum chain (ETH), where the funds were returned to investors, and a new chain called Ethereum Classic (ETC), which preserved the original ledger including the DAO hack.

How has Ethereum performed post-2020?

u200bEthereum price performance July 30, 2015 - June 30, 2025.

Ethereum price performance July 30, 2015 – June 30, 2025.

Chart via TradingView.

Ethereum reached its all-time high price of US$4,878 on November 10, 2021, during the peak of the 2020–2021 crypto bull run. The rally was driven by a convergence of factors: institutional adoption of crypto, a massive expansion of decentralized finance (DeFi), and explosive interest in NFTs, most of which were built on Ethereum’s ERC-721 standard.

By late 2021, Ethereum was settling billions in daily transaction volume and powering thousands of decentralized applications, cementing its position as the leading smart contract platform.

However, the peak was short-lived. Inflation fears and global risk aversion in early 2022 triggered a sharp correction across risk assets, including crypto. Ethereum’s price dipped below US$1,000 in June 2022 amid cascading liquidations and platform collapses like Terra and Celsius.

Still, even through the drawdown, Ethereum remained the backbone of DeFi, NFT markets, and layer-2 innovation, setting the stage for its long-planned transition to proof-of-stake later that year.

In the years that followed the fork, Ethereum faced growing pressure to scale and reduce its environmental impact, particularly as DeFi and NFT activity surged.

These challenges set the stage for a major protocol overhaul: Ethereum’s transition from Proof-of-Work (PoW) to Proof-of-Stake (PoS) was considered to be one of the most ambitious technical feats in blockchain history. Officially known as “the Merge,” the upgrade combined Ethereum’s execution layer (the mainnet) with the Beacon Chain, which introduced staking-based consensus.

The Merge took place in September 2022 and the environmental impact was immediate: Ethereum’s energy consumption dropped by over 99 percent.

While the Merge had little short-term effect on price, it marked a crucial moment for Ethereum’s long-term viability. At the time of the upgrade, ETH was trading at around US$1,600, which was a sharp decline from its all-time high of US$4,891 in November 2021 during the height of the crypto bull market.

That price peak had been driven by unprecedented network demand as NFTs and decentralized finance exploded in popularity, both largely built on Ethereum. By mid-2022, however, macroeconomic tightening, rising interest rates, and a series of high-profile crypto failures, including the collapse of TerraUSD and the insolvency of major lending platforms, had triggered a broad downturn.

After the Merge, ETH remained volatile. It already lost ground by as much as 70 percent against crypto leader Bitcoin since the Merge, and the introduction of EIP-1559 in 2021 had already created a more deflationary pressure on ETH supply through base fee burns.

Despite this setback, ETH showed relative resilience compared to many altcoins. In 2023, Ethereum hovered mostly between US$1,200 and US$2,100, with price movements closely tracking investor sentiment toward regulatory developments, Bitcoin’s performance, and broader market liquidity. Institutional interest in Ethereum also grew during this period, with more funds launching ETH products and staking services expanding.

Entering 2024, Ethereum gained momentum amid improving macroeconomic conditions and renewed optimism about real-world applications for blockchain technology. The network saw moderate success in sectors like tokenized assets, layer-2 infrastructure, and decentralized identity.

ETH briefly reclaimed the US$4,000 level in early March 2024 before retreating again due to renewed regulatory scrutiny in the US. Despite the pullback, Ethereum remained the second-largest cryptoasset by market capitalization and retained the majority share of developer activity across all chains.

The 2025 Swing

Ethereum 1-year price performance, July 28, 2024 - July 28, 2025.

Ethereum 1-year price performance, July 28, 2024 – July 28, 2025.

Chart via TradingView.

Ethereum, as well as the rest of the crypto landscape, saw a full positive swing in 2025 as regulatory clarity dominated the first half of the year.

In June, the US Senate approved the Guiding and Establishing National Innovation for US Stablecoins (GENIUS) Act with bipartisan support. President Donald Trump, now serving his second term, publicly backed the bill, calling it “a win for American innovation and financial leadership.”

The GENIUS Act establishes a regulatory framework for US-pegged stablecoins, requiring full reserve backing, independent audits, and federal licensing for large issuers. It also clarifies that qualifying stablecoins are not securities, pulling them out of the SEC’s jurisdiction and instead aligning oversight with banking regulators like the OCC and Federal Reserve.

Crucially, the law defines “payment stablecoins” as a new category of digital cash, and Ethereum has emerged as one of the largest beneficiaries of this policy shift. The majority of dollar-backed stablecoins, which include USDC, USDT, and newer entrants like PayPal USD, are issued and transacted on Ethereum.

The GENIUS Act’s legal recognition of stablecoins has given institutional players more confidence to engage with Ethereum-based infrastructure.

As a result, capital inflows into Ethereum have accelerated, with analysts noting a sharp uptick in demand for ETH as a “platform asset” powering tokenized dollars and digital settlement rails.

ETH’s price also soon followed. Following the Senate’s approval of the GENIUS Act in June 2025, ETH jumped over 25 percent in two weeks, briefly reaching US$3,824 — outperforming Bitcoin and breaking out of a multi-month consolidation range.

The act has also prompted strategic shifts among financial institutions. BlackRock, Fidelity, and JPMorgan have expanded their Ethereum-based offerings, including on-chain fund administration, tokenized treasuries, and collateralized lending protocols that rely on smart contracts.

Several US banks are also piloting internal payment rails using tokenized dollars on Ethereum rollups.

What’s next for Ethereum?

Buterin himself has acknowledged that Ethereum’s current roadmap is not the end. Speaking in late 2022 before the Merge, he noted that “Ethereum is 55 percent complete.”

The long-term vision includes greater privacy features, zero-knowledge proofs for secure scalability, and expanding the reach of dApps to a billion users.

As of mid-2025, Ethereum currently trades around US$3,400, buoyed by strong institutional adoption, continued growth of layer-2 networks like Arbitrum and Base, and early signs of real-world asset tokenization gaining traction among banks and fintech firms.

While Ethereum’s price remains well below its 2021 peak, its performance since 2020 reflects growing maturity, with fewer speculative surges and more interest anchored in a more crypto-friendly environment.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investor Insight

With high-quality, drill-ready assets with world-class discovery potential, Piche Resources is a compelling business case for investors looking to leverage a bull market for uranium and gold.

Overview

Piche Resources (ASX:PR2) is an ASX-listed mineral exploration company focused on uranium and gold exploration in Tier-1 jurisdictions: Western Australia and Argentina. The company holds 100 percent ownership of all of its projects and is supported by a highly experienced board and technical team.

Maps of mining projects in Western Australia and Argentina Including assets of Piche Resources

Targeting globally significant discoveries in Tier-1 mineral provinces

Piche’s portfolio includes the advanced-stage Ashburton uranium project in Western Australia and two large-scale exploration projects in Argentina: the Cerro Chacon gold-silver project and the Sierra Cuadrada uranium project. These projects have delivered high-grade exploration results and are drill-ready, positioning the company to unlock significant shareholder value through systematic exploration programmes.

Piche has an internationally recognized board focused on creating long-term shareholder value, and an in-country technical team in Argentina with a proven track record of taking projects from discovery through to development.

Company Highlights

  • Flagship Ashburton uranium project in Western Australia with recent high-grade drilling results over wide intercepts.
  • Sierra Cuadrada uranium project in Argentina showing extensive near-surface mineralisation with assays up to 2.86 percent U₃O₈.
  • Cerro Chacon gold-silver project with high-grade surface results (up to 11.65 g/t gold and 333.7 g/t silver) across a 14 km mineralised corridor.
  • Fully permitted and EIA-approved for drilling at Cerro Chacon (Chacon South and Middle).
  • Large, 100-percent-owned tenement package across all projects (Ashburton: 335 sq km; Cerro Chacon: 414 sq km; Sierra Cuadrada: 1,310 km²).
  • Board of directors includes former leaders of Peninsula Energy, Orano, Rio Tinto Uranium and Barrick Gold.
  • Upcoming drill campaigns planned at Cerro Chacon and Ashburton to test multiple high-priority targets.

Key Projects

Gold: Cerro Chacon, Argentina

Geological map and field survey of Piche Resources

Cerro Chacon interpreted geology and tenement holding

Cerro Chacon is a large-scale, early-stage gold-silver exploration project located in the Chubut Province of Argentina. The project is situated within a region known for hosting world-class low-sulphidation epithermal systems, including Cerro Negro and Cerro Vanguardia. With multiple gold-bearing structures confirmed over a 14 km corridor, Cerro Chacon is emerging as a highly promising and underexplored precious metals system with substantial scale and grade potential.

Project Highlights

Location: ~40 km southwest of Paso de Indios, Chubut Province

Tenure: 414 sq km across multiple tenements

Highlights:

  • A 14 km-long mineralised corridor has been delineated across Chacon Grid, La Javiela and Toro Hosco prospects.
  • High-grade geochemical results include:
    • 11.65 g/t gold and 120.3 g/t silver at Toro Hosco
    • 333.7 g/t silver, 9.48 percent lead, and 8.57 percent zinc at La Javiela South
  • Maiden RC drilling programme of 57 holes (7,905 m) scheduled across three main targets:
    • Chacon Grid: 45 holes (5,590 m)
    • La Javiela: 8 holes (1,740 m)
    • Toro Hosco: 4 holes (575 m)
  • EIA approvals for Chacon South and Chacon Middle were received in May 2025, enabling drilling to proceed.
  • Vein systems range from 2 to 6 km in strike length and up to 50 m in width; hosted within structurally controlled low-sulphidation epithermal veins (LSEV).

Uranium: Ashburton Project, Australia

Geological map showing Piche Resources

The Ashburton project is Piche’s flagship uranium exploration asset in Australia, situated in the Pilbara region of Western Australia. Located within a historically underexplored but highly prospective unconformity-related uranium district, the project provides the company with strong leverage to the growing global demand for uranium. The project is geologically analogous to world-class Proterozoic uranium systems, with multiple confirmed mineralised zones and a regional corridor of 60 km.

Project Highlights

  • Location: Pilbara region, ~1,150 km north of Perth
  • Tenure: 335 sq km following the recent application for tenement E52/4461 (214 sq km), adding to the existing 122 sq km holdings.
  • Highlights:
    • 2024 RC and diamond drilling confirmed high-grade uranium mineralisation at multiple stratigraphic levels.
    • Best intercepts include:
      • 3.45 m @ 5,129 ppm eU₃O₈ from 137.62 m (ARC006)
      • 10.48 m @ 1,412 ppm eU₃O₈ from 114.30 m (ADD005)
      • 2.42 m @ 2,681 ppm eU₃O₈ from 155.10 m (ADD003).
      • 7.86 m @ 2,266 ppm eU₃O₈ from 105.42 m (ADD006)
    • The company has outlined a 60 km structural corridor hosting multiple uranium occurrences including Angelo A & B, Canyon Creek, Ristretto and Atlantis.
    • Atlantis prospect: historical drilling returned up to 7,400 ppm U₃O₈ over 2.2 m; rock chip samples have returned up to 37 percent U₃O₈.

Uranium: Sierra Cuadrada, Argentina

Sierra Cuadrada is Piche’s primary uranium asset in Argentina, covering a vast area within the San Jorge Basin. This large-scale project has demonstrated strong surface uranium mineralisation with multiple drill-ready prospects. With mineralisation confirmed across extensive zones and supported by historical radiometric and geochemical data, Sierra Cuadrada has the potential to host multiple Tier-1 uranium deposits in a cost-effective, near-surface setting.

Geological map Piche Resources

Teo 5 and 6 prospect 2024 auger drill programme

Project Highlights:

Location: San Jorge Basin, ~200 km north of Comodoro Rivadavia

Tenure: 1,310 sq km across multiple licences

Highlights:

  • The project area contains broad, flat-lying mineralisation at multiple stratigraphic levels.
  • High-grade uranium assays include:
    • 28,650 ppm U₃O₈ (2.86 percent) from rock chip sampling at Teo 8
    • 24,017 ppm U₃O₈ from channel sampling
    • 2,772 ppm U₃O₈ over 0.5m from auger drill sample
  • Mineralised zones extend over a strike of 60 sq km, with confirmed targets on the majority of tenements.
  • 2024 auger drilling and sampling confirmed uranium continuity across a sandstone and conglomerate sedimentary package with 14 samples exceeding 200 ppm U₃O₈.
  • Rock chip sampling has returned 114 samples >200ppm U₃O₈
  • RC drilling is planned to follow up on anomalies identified in the auger and channel sampling programmes.

Management Team

John (Gus) Simpson – Executive Chairman

John Simpson has over 37 years of experience in mineral exploration, development and mining. Previously the executive chairman and founder of Peninsula Energy Limited (ASX:PEN), a USA uranium producer.

Stephen Mann – Managing Director

Stephen Mann is a geologist with over 40 years of experience in exploration, discovery and development of mining projects, including 20 years in the uranium sector. Formerly the Australian managing director of Orano, the world’s third-largest uranium producer.

Pablo Marcet –Executive Director

Pablo Marcet is a senior geoscientist with 38 years of experience in exploration, discovery and development of mineral deposits. Currently an independent director of lithium producer Arcadium Lithium (NYSE:ALTM) and previously a director of Barrick Gold (NYSE:GOLD) and U3O8 (TSX:UWE).

Clark Beyer – Non-executive Director

Clark Beyer is an internationally recognized nuclear industry executive with over 35 years of experience. Formerly the managing director of Rio Tinto Uranium and currently principal of Global Fuel Solutions, providing strategic consulting to the international uranium and nuclear fuels market.

Stanley Macdonald – Non-executive Director

Stanley Macdonald is a nationally recognized mining entrepreneur, founding director and instrumental in the success of numerous ASX-listed companies, such as Giralia Resources, Northern Star and Redhill Iron. He is currently a director of Zenith Minerals.

This post appeared first on investingnews.com

The Senate confirmed President Donald Trump’s nominee Emil Bove as a federal judge Tuesday, handing a controversial leader at the Department of Justice a lifetime role on a powerful appellate court.

Bove was narrowly confirmed to the U.S. Court of Appeals for the 3rd Circuit in a 50-49vote with no support from Democrats. His confirmation followed a contentious weeks-long vetting process that included three whistleblower complaints and impassioned outside figures voicing both support and opposition to his nomination.

Senate Judiciary Committee Chairman Chuck Grassley, R-Iowa, said from the Senate floor before the vote that he supported Bove and believed the nominee had been the target of ‘unfair accusations and abuse.’

‘He has a strong legal background and has served his country honorably. I believe he will be a diligent, capable, and fair jurist,’ Grassley said. 

Bove’s ascension to the appellate court marks a peak in his legal career.

He started out as a high-achieving student, college athlete and Georgetown University law school graduate. He went on to clerk for two federal judges and worked for about a decade as a federal prosecutor in the Southern District of New York, leading high-profile terrorism and drug trafficking cases through 2019.

Alongside Todd Blanche, now a deputy attorney general, Bove led Trump’s personal defense team during the president’s criminal prosecutions. Blanche told Fox News Digital in an interview last month that Bove was a ‘brilliant lawyer’ who authored the vast majority of their legal briefs for Trump’s cases. In a letter to the Senate, attorney Gene Schaerr called Bove’s brief writing ‘superb.’

Bove will leave behind his job as principal associate deputy attorney general at the DOJ. Attorney General Pam Bondi congratulated him in a statement.

‘This is a GREAT day for our country,’ Bondi wrote on X. ‘I cannot thank Emil enough for his tireless work and support at @TheJusticeDept. He will be missed — and he will be an outstanding judge.’

Two Republicans, Sens. Lisa Murkowski of Alaska and Susan Collins of Maine, voted against Bove.

Democrats and some who crossed paths with Bove during his time in New York and at DOJ headquarters fiercely opposed his nomination and said he was unqualified.

One whistleblower, Erez Reuveni, had become a successful prosecutor at the DOJ over the last 15 years when he was fired under Bove’s watch. Reuveni said he was party to a meeting in March in which Bove floated defying any court orders that would hinder one of Trump’s most legally questionable deportation plans, a claim Bove denies. Reuveni also said the culture at the DOJ, particularly during the most intense moments of immigration lawsuits, involved misleading federal judges and was like nothing he had experienced during his tenure, which included Trump’s first term.

Two other anonymous whistleblowers emerged at the eleventh hour during the confirmation process and vouched for Reuveni’s claims.

A spokeswoman for Grassley told Fox News Digital the third whistleblower only brought claims to Senate Democrats and did not attempt to engage with Grassley. Grassley’s staff eventually met with the whistleblower’s lawyers after the chairman’s office reached out, the spokeswoman said.

Grassley said his staff interviewed more than a dozen people to vet the initial whistleblower claims and could not find evidence that Bove urged staff to defy the courts.

‘Even if you accept most of the claims as true, there’s no scandal,’ Grassley said. ‘Government lawyers aggressively litigating and interpreting court orders isn’t misconduct—it’s what lawyers do.’

While in New York, Bove also alienated some colleagues. In 2018, a band of defense lawyers said in emails reported by The Associated Press that Bove could not ‘be bothered to treat lesser mortals with respect or empathy.’ Another lawyer who had interactions with Bove in New York told Fox News Digital he was a ‘bully’ who browbeat people. 

A group that opposes Bove’s nomination, Justice Connection, published a letter signed by more than 900 former DOJ employees calling for the Senate to reject Bove’s nomination.

Among their concerns was that Bove led the controversial dismissal of Democratic New York City Mayor Eric Adams’ federal corruption charges. Several DOJ officials resigned in protest over Bove’s orders to toss out the charges. In the letter, the former employees said Bove has been ‘trampling over institutional norms’ and that he lacked impartiality.

Senate Judiciary Committee Democrats, in an unusual move, staged a walkout at a hearing on Bove before a recent vote to advance his nomination. Senate Minority Leader Chuck Schumer, D-N.Y., called him a ‘henchman,’ a description Democrats have widely adopted for him.

‘He’s the extreme of the extreme,’ Schumer told reporters. ‘He’s not a jurist. He’s a Trumpian henchman. That seems to be the qualification for appointees these days.’

Bove defended himself against critics during his confirmation hearing.

‘I am not anybody’s henchman. I’m not an enforcer,’ Bove said. ‘I’m a lawyer from a small town who never expected to be in an arena like this.’

Fox News’ Alex Miller contributed to this report.


This post appeared first on FOX NEWS

From established players to up-and-coming firms, Canada’s pharmaceutical company landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.

1. Cipher Pharmaceuticals (TSX:CPH,OTC:CPHRF)

Year-over-year gain: 48.2 percent
Market cap: C$330.79 million
Share price: C$12.33

Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well. Cipher began trading on the OTCQX Best Market under the symbol CPHRF in early 2024.

In addition to its current portfolio, Cipher has acquired Canadian rights to CF-101, a dermatology treatment for moderate to severe plaque psoriasis is currently expected to undergo Phase III clinical trials. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.

In 2024, Cipher announced it had signed a definitive asset purchase agreement with ParaPRO for its US-based Natroba operations and global product rights, and the news caused Cipher’s share price to spike significantly.

During its Q1 results reporting in May 2025, the company announced a US$15 million debt repayment.

2. HLS Therapeutics (TSX:HLS)

Year-over-year gain: 42.03 percent
Market cap: C$154.95 million
Share price: C$4.90

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs. Key commercial products include Vascepa, Clozaril for treatment-resistant schizophrenia and cholesterol-lowering therapies NEXLETOL and NEXLIZET.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

3. Medexus Pharmaceuticals (TSX:MDP,OTC:MEDXF)

Year-over-year gain: 23.25 percent
Market cap: C$92.9 million
Share price: C$2.81

Medexus Pharmaceuticals specializes in bringing drugs to treat rare diseases to North America. The company manages the entire process through its fully integrated operations, from acquiring and developing drugs to marketing and selling them. Some of its key products include treatments for hemophilia B and rheumatoid arthritis, as well as a line of drugs for autoimmune diseases like lupus and allergy treatments.

In November 2024, Medexus Pharmaceuticals announced it had successfully negotiated with the pan-Canadian Pharmaceutical Alliance to make treosulfan, which Medexus commercialized in Canada under the name Trecondyv, available to publicly funded drug programs and patients. Trecondyv is indicated as part of conditioning treatment prior to bone marrow transplants in patients with certain types of blood cancers.

In addition to Canada, Medexus has the exclusive commercialization rights to treosulfan in the US, where it received approval from the US Food and Drug Administration (FDA) in January 2025.

4. Satellos Bioscience (TSXV:MSCL,OTC:MSCLF)

Year-over-year gain: 18 percent
Market cap: C$102.26 million
Share price: C$0.59

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies to regenerate and repair muscle tissue by targeting the specific biological pathways involved. Its lead candidate SAT-3247 targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

The company began enrolment for a multiple-ascending-dose arm of the Phase 1 study for SAT-3247 last November after no drug-related adverse events were reported in the single-ascending-dose group.

In May of this year, Satellos announced results from its Phase 1b trial, reporting SAT-3247 has shown positive safety and pharmacokinetic data and encouraging early functional results, clearing the path for a planned Phase 2 trial.

5. NurExone Biologic (TSXV:NRX,OTC:NRXBF)

Year-over-year gain: 1.41 percent
Market cap: C$44.18 million
Share price: C$0.72

NurExone Biologic is the biopharmaceutical company behind ExoTherapy, a drug delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US Food and Drug Administration (FDA) in October 2023, meaning it has been recognized as a potential treatment for rare medical conditions. The designation makes it eligible for incentives such as market exclusivity and regulatory assistance aimed at accelerating its development and approval.

The company released preclinical results from animal testing evaluating the efficacy of its nano-drug ExoPTEN in restoring lost vision at the end of 2024. In July 2025, preclinical studies indicated that ExoPTEN could improve walking quality in patients with spinal cord injuries.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

“Whatever is out of favor and hated at the moment, that’s probably what you need to buy,” he said. “Buy it when it’s boring and no one cares, then you get to ride the wave up.”

Barton also broke down his current portfolio, which holds a 30 percent weighting in precious metals—particularly gold—citing concerns over currency policies and the long-term upside for gold and silver.

Watch the interview above for more from Barton on the similarities between poker and resource investing.

Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

As the global push toward electrification accelerates, lithium remains a critical piece of the energy transition.

Continued oversupply remained a persistent headwind for lithium prices through the first half of 2025. Demand for the battery metal jumped 29 percent year-over-year in 2024, fueled by surging electric vehicle sales and rising power needs from sectors like data centers and heavy industry.

Fastmarket’s analysts expect lithium demand to grow 12 percent annually through 2030, supported by structural trends such as renewable energy integration and battery energy storage.

However, a rapid increase in global supply — particularly from China, Australia and South America — has driven prices to multi-year lows, raising concerns about project economics and the sustainability of new production.

Against this backdrop, Canadian lithium stocks are gaining attention as investors look for companies positioned to benefit from long-term demand growth while navigating short-term price pressure.

1. NOA Lithium Brines (TSXV:NOAL)

Year-to-date gain: 58.82 percent
Market cap: C$488.32 million
Share price: C$0.30

NOA is a lithium exploration and development company with three projects in Argentina’s Lithium Triangle region. The company’s flagship Rio Grande project and prospective Arizaro and Salinas Grandes land packages total more than 140,000 hectares.

As NOA works to advance its flagship asset, the company brought on Hatch in April to lead the preliminary economic assessment (PEA).

The PEA will evaluate the project’s economic and development potential with a target production of 20,000 metric tons of lithium carbonate equivalent (LCE) annually, with a scalable plant design that could double capacity to 40,000 metric tons per year.

NOA has also been working to secure a water source in the arid region through a drilling program targeting fresh water. In late June, the company discovered a fresh water source at the project, located near high-grade lithium zones in the project’s northeast area. According to the company, the location means the water source could support future production facilities or evaporation ponds.

The well, drilled to 190 meters in the northern part of the property, is being tested and developed.

Shares of NOA reached a year-to-date high C$0.425 on July 17, 2025.

2. Wealth Minerals (TSXV:WML)

Year-to-date gain: 40 percent
Market cap: C$23.93 million
Share price: C$0.07

Wealth Minerals is focused on the acquisition and development of lithium projects in Chile, including the Yapuckuta project in Chile’s Salar de Atacama, as well as the Kuska Salar and Pabellón projects near the Salar de Ollagüe.

Wealth Minerals’ shares spiked to a year-to-date high of C$0.095 on February 9, 2025, following the company’s acquisition of the Pabellón project.

According to Wealth, Pabellón has been shortlisted by Chile’s Ministry of Mining as a potential site for a Special Lithium Operation Contract based on its geological and environmental suitability. Located in Northern Chile near the Bolivia border, the project spans 7,600 hectares across 26 exploration licenses about 70 kilometers south of the Salar de Ollagüe.

In May, Wealth formed a joint venture with the Quechua Indigenous Community of Ollagüe to advance the Kuska project. The new entity, Kuska Minerals SpA, is 95 percent owned by Wealth and 5 percent by the community, which also holds anti-dilution rights and a seat on the five-member board.

3. Avalon Advanced Materials (TSX:AVL)

Year-to-date gain: 37.5 percent
Market cap: C$38.26 million
Share price: C$0.055

Avalon Advanced Materials is a Canadian mineral development company focusing on integrating the Ontario lithium supply chain. Avalon is developing the Separation Rapids and Snowbank lithium projects near Kenora, Ontario, and the Lilypad lithium-cesium project near Fort Hope, Ontario.

Separation Rapids and Lilypad are part of a 40/60 joint venture between Avalon and SCR Sibelco, with Sibelco serving as the operator.

Avalon started the year with a revised mineral resource estimate for the Separation Rapids project, which boosted resources in the measured and indicated category by 28 percent.

Company shares rose to C$0.07, a year-to-date high, on July 15, the day after Avalon released its results for its fiscal quarter ended May 31.

A week later, Avalon announced an additional C$1.3 million in funding through its C$15 million convertible security agreement with Lind Global Fund II. The drawdown, expected to close within two weeks, will support project development and general corporate needs, according to the company.

4. Frontier Lithium (TSXV:FL)

Year-to-date gain: 20 percent
Market cap: C$125.41 million
Share price: C$0.54

Pre-production mining company Frontier Lithium aims to be a strategic and integrated supplier of premium spodumene concentrates as well as battery-grade lithium salts in North America.

The company’s flagship PAK lithium project, which is a joint venture with Mitsubishi (TSE:8058), holds the “largest land position and resource” in a premium lithium mineral district located in the Great Lakes region of Ontario, Canada. Frontier also owns the Spark deposit, located northwest of the PAK project.

Shares of Frontier Lithium reached a year-to-date high of C$0.79 on March 4. The stock uptick coincided with a government release reporting the federal and provincial governments supported the company’s plans to build a critical minerals refinery in Northern Ontario.

Once complete, the proposed lithium conversion facility will process lithium from the PAK mine project into approximately 20,000 metric tons of lithium salts per year.

In late May, Frontier released a definitive feasibility study for the mine and mill segment of its PAK project. The study outlines a 31 year mine life with average production of 200,000 metric tons of spodumene concentrate. As for the economics, it projects net revenue of C$11 billion, an after-tax NPV of C$932 million and a 17.9 percent internal rate of return.

5. Century Lithium (TSXV:LCE)

Year-to-date gain: 17.31 percent
Market cap: C$51.58 million
Share price: C$0.30

US-focused Century Lithium is currently advancing its Angel Island lithium project in Esmeralda County, Nevada. The company is also engaged in the pilot testing phase at its on-site lithium extraction facility, which will process material from the lithium-bearing claystone deposit.

On May 6, Century Lithium announced the successful completion of testwork on the direct lithium extraction (DLE) process at its demonstration plant.

The results exceeded expectations, showing 91.6 percent lithium recovery and an eluate grade of 575 milligrams per liter (mg/L) from a 328 mg/L lithium concentrate feed. The company says these improvements could significantly reduce capital and operating costs at its Angel Island project.

Shares of Century Lithium registered a year-to-date high of C$0.49 on May 19.

Recently, the company participated in First Phosphate’s (CSE:PHOS,OTCQB:FRSPF) successful production of commercial-grade lithium iron phosphate (LFP) 18650 battery cells.

As noted in the press release, the cells were made using North America-sourced materials, including lithium carbonate from Century’s Angel Island project in Nevada that was processed at its demonstration plant alongside high-purity phosphoric acid and iron from First Phosphate’s Bégin-Lamarche project in Québec, Canada.

Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Maritime Resources Corp. (TSXV: MAE,OTC:MRTMD) (‘Maritime’ or the ‘Company’) is pleased to announce the full cash repayment of the US$5 million principal amount owed under its non-convertible senior secured notes due on August 14, 2025 (the ‘Notes’), along with accrued and unpaid interest for the month of July 2025. In order to repay the Notes, the Company used the proceeds from its recently completed brokered ‘best efforts’ private placement offering of common shares in the capital of the Company, as announced on July 17, 2025. Payment for the Notes was processed today through Computershare Trust Company of Canada.

Garett Macdonald, Chief Executive Officer of Maritime, commented: ‘We would like to take this opportunity to thank each of the noteholders for their support of the acquisition of the Point Rousse Project which included the Pine Cove Mill in August 2023 through the senior secured note facility. The Company is once again debt-free with the full repayment of the Notes.’

About Maritime Resources Corp.

Maritime (TSXV: MAE,OTC:MRTMD) is a gold exploration and development company focused on advancing the Hammerdown Gold Project in the Baie Verte District of Newfoundland and Labrador, a top tier global mining jurisdiction. Maritime holds a 100% interest directly and subject to option agreements entitling it to earn 100% ownership in the Green Bay Property which includes the former Hammerdown gold mine and the Orion gold project. Maritime controls over 439 km2 of exploration land including the Green Bay, Whisker Valley, Gull Ridge and Point Rousse projects. Mineral processing assets owned by Maritime in the Baie Verte mining district include the Pine Cove mill and the Nugget Pond gold circuit.

On Behalf of the Board:

Maritime Resources Corp.

Garett Macdonald, MBA, P.Eng.
President and CEO
Phone: (416) 365-5321
info@maritimegold.com 
www.maritimeresourcescorp.com

Twitter
Facebook
LinkedIn
YouTube

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260608

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

 

Westport Fuel Systems Inc. (‘Westport’ or the ‘Company’) (TSX:WPRT Nasdaq:WPRT), today announced the successful closing of the previously announced transaction to divest its Light-Duty Segment and outlines its strategic vision for future growth, emphasizing expansion of market share, entering new markets and right sizing its current operations.

 

Today, Westport closed the sale of the Light-Duty Segment to a wholly-owned investment vehicle of Heliaca Investments Coöperatief U.A. (‘Heliaca Investments’), a Netherlands based investment firm supported by Ramphastos Investments Management B.V., a prominent Dutch venture capital and private equity firm (the ‘Transaction’). The Transaction, initially announced on March 31, 2025, includes the sale of Westport Fuel Systems Italia S.r.l., encompassing the Light-Duty OEM, delayed OEM, and independent aftermarket businesses. Total consideration for the assets was a base price of approximately $79.5 million (€67.7 million), subject to certain adjustments, along with potential earnouts of up to a revised estimate of $3.9 million (€3.3 million) based on future performance milestones.

 

‘The successful completion of the disposition of our Light-Duty Segment marks a pivotal step in strengthening our balance sheet,’ said Dan Sceli, Chief Executive Officer of Westport Fuel Systems. ‘More importantly, it allows Westport to sharpen our focus on the larger, higher-growth opportunities ahead, including providing the most economical solutions for heavier duty and high horse power commercial mobility and industrial applications that also deeply decarbonize these challenging segments – where we believe our products and technologies can deliver the greatest value.’

 

  The New Westport  

 

With the successful completion of the Light-Duty Segment divestiture, Westport is taking the necessary steps to execute on a new and focused integrated business strategy. The Company recognizes the evolving macroeconomic environment and is positioning itself to capitalize on renewed market momentum, drive operational excellence, and deliver on key financial objectives.

 

‘The transportation landscape is shifting, and customer demand for cleaner, smarter, and more sustainable solutions continues to accelerate,’ added Sceli. ‘We’re seeing renewed attention on CNG and LNG fuelled platforms and Westport is uniquely positioned to deliver the necessary products and technologies. By leveraging our core strengths in fuel-agnostic, high-pressure fuel systems, we aim to meet growing market demand and provide our customers with reliable solutions that perform – and in many cases are more affordable than the incumbant engines.’

 

During the upcoming Q2 financial results conference call, Westport will be covering additional details about the transaction and Westport’s strategy ahead. We will focus on key priorities, including:

 

  • Cespira: Strategic market expansion and technology leadership in heavy-duty transportation and off road high horse power mobility
  •  

  • High Pressure Controls and Systems: Complementing the energy transition with versatile solutions that support multiple powertrain platforms
  •  

  • Westport Financial Initiatives: Balancing opportunity scale, execution performance, and dynamic market conditions
  •  

Westport’s key focus going forward recognizes both the opportunities and headwinds in overall market conditions. We have initiated a comprehensive internal process to review additional ways to maximize our economic benefit from this recent transaction for our stakeholders. We look forward to providing additional insight and updates when we report Q2 2025 results on Monday, August 11, 2025, after market close.

 

  About Westport Fuel Systems  

 

Westport is a technology and innovation company connecting synergistic technologies to power a cleaner tomorrow. As a leading supplier of affordable, alternative fuel, low-emissions transportation technologies, we design, manufacture, and supply advanced components and systems that enable the transition from traditional fuels to cleaner energy solutions.

 

Our proven technologies support a wide range of clean fuels – including natural gas, renewable natural gas, and hydrogen – empowering OEMs and commercial transportation industries to meet performance demands, regulatory requirements, and climate targets in a cost-effective way. With decades of expertise and a commitment to engineering excellence, Westport is helping our partners achieve sustainability goals – without compromising performance or cost-efficiency – making clean, scalable transport solutions a reality.

 

 Westport Fuel Systems is headquartered in Vancouver, Canada. For more information, visit   www.westport.com   .

 

  Cautionary Note Regarding Forward-Looking Statements  

 

  This press release contains forward-looking statements, including statements regarding the anticipated benefits of the Transaction, including potential earn-out payments, the ability to strengthen our balance sheet, the ability to capitalize on higher-   growth opportunities   ,   and our expectations regarding the future success of our business.   Other forward-looking statements included in the release include those relating to Westport’s future strategic plans, business opportunities and use of the Transaction proceeds. These statements are neither promises nor guarantees but involve known and unknown risks and uncertainties and are based on both the views of management and assumptions that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activities, performance, or achievements expressed in or implied by these forward-looking statements. These risks, uncertainties, and assumptions include those related to governmental policies, regulation and approval, the achievement of the performance criteria required for the earnout described above, purchase price adjustments contained in the Agreement, the demand for our products, as well as other risk factors and assumptions that may affect our actual results, performance, or achievements, as discussed in our most recent Annual Information Form and other filings with securities regulators. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in these forward-looking statements except as required by National Instrument 51-102. The contents of any website referenced in this press release are not incorporated by reference herein   .  

 

  Investor Inquiries:  
Investor Relations
T: +1 604-718-2046
E:   invest@westport.com   

 

  Primary Logo 

 

 

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

The Senate confirmed President Donald Trump’s pick to lead the Centers for Disease Control and Prevention after his first choice struggled to gain support.

Susan Monarez, a longtime fixture in Washington who has taken on leadership positions in a number of government public health roles, was confirmed by the Senate on Tuesday, crossing yet another position off the lengthy and growing number of nominees awaiting confirmation.

Monarez was confirmed on a 51to 47party line vote.

Across her roughly two-decade career in D.C., she has served as deputy director of the Advanced Research Projects Agency for Health within the Department of Health and Human Services and in roles at the White House, including at the Office of Science and Technology Policy and the National Security Council.

She is the first CDC director to undergo the Senate confirmation process after a new law changed the requirement in 2023. Prior to her confirmation, Monarez had served as the acting director of the CDC since the beginning of this year.

But Monarez, who has a Ph.D. in microbiology and immunology, was not Trump’s first pick to lead the public health agency, which is tasked with protecting Americans from public health threats.

Trump tapped Monarez in March shortly after withdrawing his nomination of Dr. David Weldon, a former House member, after it was clear that he couldn’t get enough votes from Senate Republicans to make it across the finish line.

He lauded Monarez’s credentials, and charged that Americans had ‘lost confidence’ in the CDC.

‘Dr. Monarez will work closely with our GREAT Secretary of Health and Human Services, Robert Kennedy Jr,’ he said on social media at the time. ‘Together, they will prioritize Accountability, High Standards, and Disease Prevention to finally address the Chronic Disease Epidemic and, MAKE AMERICA HEALTHY AGAIN!’

But questions also linger on how well Monarez and Health and Human Services Secretary Robert F. Kennedy Jr. might work together.

During her confirmation hearing last month, Senate Democrats grilled Monarez over whether she agreed with Kennedy’s positions on vaccines. Kennedy has long been outspoken about his skepticism regarding vaccines, particularly COVID-19 vaccines.

The CDC has been hit with thousands of staff cuts and resignations and subject to changes in vaccine policy — notably Kennedy’s decision to remove the COVID-19 from the vaccine schedule for pregnant women and healthy children — in the last six months. 

‘I think vaccines save lives. I think that we need to continue to support the promotion of utilization of vaccines,’ Monarez said during her confirmation hearing.

Her confirmation also comes as Kennedy, in his budget request for the HHS, seeks a slash in funding to the CDC of nearly 50%, or from about $9.2 billion to $4.2 billion, for the upcoming fiscal year.

But Kennedy made clear in an X post at the time of her nomination that he supports Monarez to take on the position.

‘I handpicked Susan for this job because she is a longtime champion of MAHA values, and a caring, compassionate and brilliant microbiologist and a tech wizard who will reorient CDC toward public health and gold-standard science,’ he said. ‘I’m so grateful to President Trump for making this appointment.’

And an HHS spokesperson told Fox News Digital, ‘Once Dr. Monarez is confirmed, the Secretary looks forward to working with her to advance common-sense policies that will Make America Healthy Again.’


This post appeared first on FOX NEWS